南通大学学报(医学版)
南通大學學報(醫學版)
남통대학학보(의학판)
JOURNAL OF NANTONG UNIVERSITY(MEDICAL SCIENCES)
2014年
2期
101-103
,共3页
华青%陈强%计文明%黎曼
華青%陳彊%計文明%黎曼
화청%진강%계문명%려만
顽固性高磷血症%维持性血液透析%碳酸镧
頑固性高燐血癥%維持性血液透析%碳痠鑭
완고성고린혈증%유지성혈액투석%탄산란
refractory hyperphosphatemia%maintenance hemodialysis%lanthanum carbonate
目的:观察碳酸镧治疗血液透析患者顽固性高磷血症的有效性和安全性。方法:选择16例存在顽固性高磷血症的维持性血液透析(maintenance hemodialysis,MHD)患者,每日3餐餐中予嚼服碳酸镧咀嚼片500 mg,4周后对血磷水平进行分析评估,并观察不良反应。结果:患者口服碳酸镧4周后血磷水平明显下降,血清磷水平由服药前(2.99±0.26) mmol/L降为(1.94±0.28) mmol/L(P<0.05),而血清钙、甲状旁腺激素等指标在治疗前后并无明显变化(P>0.05)。在服用碳酸镧过程中,2例患者出现轻微的胃部不适感,但无1例患者因严重的不良反应中断治疗。结论:碳酸镧能够安全和有效地降低MHD患者的血磷水平。
目的:觀察碳痠鑭治療血液透析患者頑固性高燐血癥的有效性和安全性。方法:選擇16例存在頑固性高燐血癥的維持性血液透析(maintenance hemodialysis,MHD)患者,每日3餐餐中予嚼服碳痠鑭咀嚼片500 mg,4週後對血燐水平進行分析評估,併觀察不良反應。結果:患者口服碳痠鑭4週後血燐水平明顯下降,血清燐水平由服藥前(2.99±0.26) mmol/L降為(1.94±0.28) mmol/L(P<0.05),而血清鈣、甲狀徬腺激素等指標在治療前後併無明顯變化(P>0.05)。在服用碳痠鑭過程中,2例患者齣現輕微的胃部不適感,但無1例患者因嚴重的不良反應中斷治療。結論:碳痠鑭能夠安全和有效地降低MHD患者的血燐水平。
목적:관찰탄산란치료혈액투석환자완고성고린혈증적유효성화안전성。방법:선택16례존재완고성고린혈증적유지성혈액투석(maintenance hemodialysis,MHD)환자,매일3찬찬중여작복탄산란저작편500 mg,4주후대혈린수평진행분석평고,병관찰불량반응。결과:환자구복탄산란4주후혈린수평명현하강,혈청린수평유복약전(2.99±0.26) mmol/L강위(1.94±0.28) mmol/L(P<0.05),이혈청개、갑상방선격소등지표재치료전후병무명현변화(P>0.05)。재복용탄산란과정중,2례환자출현경미적위부불괄감,단무1례환자인엄중적불량반응중단치료。결론:탄산란능구안전화유효지강저MHD환자적혈린수평。
Objective: To assess the efficacy and side effects of lanthanum carbonate in maintenance hemodialysis (MHD) patients with refractory hyperphosphatemia. Methods: Sixteen MHD patients with refractory hyperphosphatemia were pre-scribed with lanthanum carbonate 500 mg for 4 weeks, three times a day in mealtime. The serum phosphorus was examined before and after treatment and the side effects was also observed. Results: After treatment, serum phosphorus decreased sig-nificantly from (2.99±0.26) mmol/L to (1.94±0.28) mmol/L (P<0.05). The serum calcium,and serum parathyroid hormone show no obvious variation(P>0.05). The side effects of lanthanum carbonate were weak, only 2 patients feel sick to their stomach. No patient interrupted therapy and no serious adverse events were observed. Conclusion: The management of hyperphos-phatemia with lanthanum carbonate in MHD patients is safe and effective.